Thursday, July 17, 2014
Alexion Pharmaceuticals Inc.
is hoping that its research collaboration with Cincinnati Children's Hospital Medical Center will help the biotech build out a
rare disease pipeline that currently is dominated by a single molecule-Soliris
The deal is Alexion's first collaboration with a clinical center and
complements its pipeline-building efforts with biotechs and academia.
than forming a new initiative, the Alexion Rare Disease Innovation Fund will
piggyback on the existing Innovation Fund. The advisory board will be expanded
to include representatives from Alexion.
A. SciBX 7(27); doi:
10.1038/scibx.2014.783 Published online July 17, 2014
AND INSTITUTIONS MENTIONED
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn.
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Moderna Therapeutics Inc., Cambridge, Mass.
Persepsys Biomedical LLC, Cincinnati, Ohio
University of Nevada, Reno, Nev.